- Home
- ORC vs CRGX Comparison
ORC vs CRGX Comparison
Compare ORC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- CRGX
- Stock Information
- Founded
- ORC 2010
- CRGX 2021
- Country
- ORC United States
- CRGX United States
- Employees
- ORC N/A
- CRGX N/A
- Industry
- ORC Real Estate Investment Trusts
- CRGX
- Sector
- ORC Real Estate
- CRGX
- Exchange
- ORC Nasdaq
- CRGX Nasdaq
- Market Cap
- ORC 660.1M
- CRGX 190.0M
- IPO Year
- ORC 2013
- CRGX 2023
- Fundamental
- Price
- ORC $7.11
- CRGX $4.40
- Analyst Decision
- ORC Hold
- CRGX Hold
- Analyst Count
- ORC 3
- CRGX 7
- Target Price
- ORC N/A
- CRGX $4.67
- AVG Volume (30 Days)
- ORC 3.7M
- CRGX 527.8K
- Earning Date
- ORC 07-24-2025
- CRGX 08-11-2025
- Dividend Yield
- ORC 20.25%
- CRGX N/A
- EPS Growth
- ORC N/A
- CRGX N/A
- EPS
- ORC 0.46
- CRGX N/A
- Revenue
- ORC $52,240,000.00
- CRGX N/A
- Revenue This Year
- ORC $46.17
- CRGX $57.81
- Revenue Next Year
- ORC $26.45
- CRGX N/A
- P/E Ratio
- ORC $15.50
- CRGX N/A
- Revenue Growth
- ORC N/A
- CRGX N/A
- 52 Week Low
- ORC $5.69
- CRGX $3.00
- 52 Week High
- ORC $9.01
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- ORC 54.77
- CRGX 55.41
- Support Level
- ORC $6.90
- CRGX $4.09
- Resistance Level
- ORC $7.13
- CRGX $4.31
- Average True Range (ATR)
- ORC 0.12
- CRGX 0.19
- MACD
- ORC 0.01
- CRGX -0.01
- Stochastic Oscillator
- ORC 91.94
- CRGX 61.61
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.